A CLINICAL STAGE COMPANY BY 2022

Multiple programs of “sole-in-class” drug-candidates:

  • The 1st regulator of Golgi trafficking: the KIF20-A inhibitor DIACC 2010, firstly in blood cancers

  • The 1st immunotherapy targeting membrane-driven CD4 T cells anergia : the anti-PLA2G1B DIACC1010 in cancers and infectious diseases with partial or total CD4 immunodeficiency


 

Contact Us

Phone:

33 (0)1 78 96 41 73

  • Twitter - Cercle blanc
  • LinkedIn

DIACCURATE SAS

3-5 impasse Reille

75014 Paris, France

© 2021 DIACCURATE with ATCG Partners